ClinicalTrials.gg
CompletedNCT00420212DEFINEUpdated Jan 26, 2015Results posted

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

A Phase 3 interventional study of BG00012 and Placebo in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 160 sites in 29 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-01-26.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,234
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
3rd of 22
1,234 · median 61
Started
2007
with 1 other
Phase 3
10 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 1st registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.

The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • relapsing
  • oral
  • remitting
  • multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:
  • Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.
  • Must have a baseline EDSS between 0.0 and 5.0, inclusive.
  • Must have relapsing-remitting disease course.

Key Exclusion Criteria:

  • Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at randomization:
  • Other chronic disease of the immune system, , acute urologic, pulmonary, gastrointestinal disease.
  • Pregnant or nursing women.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,234 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received two placebo capsules orally three times daily (TID)

    Drug: Placebo

  • Experimental
    BG00012 240 mg Twice Daily (BID)

    Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)

    Drug: BG00012

  • Experimental
    BG00012 240 mg 3 Times Daily (TID)

    Participants received two 120 mg BG00012 capsules orally three times daily (TID)

    Drug: BG00012

Interventions

  • Also known as: dimethyl fumarate, Tecfidera®

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Relapsed

    A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.

    Time frame: 2 years

Secondary outcomes

  1. Number of New or Newly Enlarging T2 Hyperintense Lesions

    The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume

    Time frame: 2 years

  2. Number of Gadolinium-enhancing T1-weighted Lesions

    The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.

    Time frame: 2 years

  3. Number of Subjects With Gadolinium (Gd)-Enhancing Lesions

    Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure "Number of Gadolinium-enhancing T1-weighted lesions"

    Time frame: 2 years

  4. Annualized Relapse Rate

    A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. \>2.0), age (\<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.

    Time frame: 2 years

  5. Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)

    The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.

    Time frame: 2 years

07

Results

Posted Jun 2, 2014

Participant flow

Subjects were screened and enrolled at 198 investigational sites in 28 countries.

Participant flow — Overall Study
MilestonePlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)
Started408410416
Completed317315320
Not completed919596
Withdrew: Adverse event224036
Withdrew: Lost to follow-up91111
Withdrew: Withdrawal by subject312219
Withdrew: Physician decision443
Withdrew: Protocol violation448
Withdrew: Death001
Withdrew: Other-unspecified211418

Outcome measures

PrimaryProportion of Subjects Relapsed

A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.

Time frame:
2 years
Reported as:
Number · Proportion of subjects,confirmed relapse
Proportion of Subjects Relapsed
Proportion of subjects,confirmed relapsePlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)
Proportion of Subjects Relapsed0.4610.2700.260
SecondaryNumber of New or Newly Enlarging T2 Hyperintense Lesions

The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume

Time frame:
2 years
Reported as:
Mean · Number of lesions
Number of New or Newly Enlarging T2 Hyperintense Lesions
Number of lesionsPlaceboBG00012 240 mg BIDBG00012 240 mg TID
Number of New or Newly Enlarging T2 Hyperintense Lesions17.0 (12.9 to 22.4)2.6 (2.0 to 3.5)4.4 (3.2 to 5.9)
SecondaryNumber of Gadolinium-enhancing T1-weighted Lesions

The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.

Time frame:
2 years
Reported as:
Mean · Number of lesions
Number of Gadolinium-enhancing T1-weighted Lesions
Number of lesionsPlaceboBG00012 240 mg BIDBG00012 240 mg TID
Number of Gadolinium-enhancing T1-weighted Lesions1.8 ± 4.150.1 ± 0.630.5 ± 1.73
SecondaryNumber of Subjects With Gadolinium (Gd)-Enhancing Lesions

Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure "Number of Gadolinium-enhancing T1-weighted lesions"

Time frame:
2 years
Reported as:
Number · Number of subjects
Number of Subjects With Gadolinium (Gd)-Enhancing Lesions
Number of subjectsPlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)
0 lesions103142130
1 lesion16810
2 lesions1312
3-4 lesions1503
>=5 lesions1817
SecondaryAnnualized Relapse Rate

A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. \>2.0), age (\<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.

Time frame:
2 years
Reported as:
Mean · Relapses per year
Annualized Relapse Rate
Relapses per yearPlaceboBG00012 240 mg BIDBG00012 240 mg TID
Annualized Relapse Rate0.364 (0.303 to 0.436)0.172 (0.138 to 0.214)0.189 (0.153 to 0.234)
SecondaryProportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)

The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.

Time frame:
2 years
Reported as:
Number · Proportion of participants
Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)
Proportion of participantsPlaceboBG00012 240 mg BIDBG00012 240 mg TID
Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)0.2710.1640.177

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—86/408 (21.1%)384/408 (94.1%)
BG00012 240 mg Twice Daily (BID)—74/410 (18%)394/410 (96.1%)
BG00012 240 mg 3 Times Daily (TID)—65/416 (15.6%)393/416 (94.5%)
Total BG00012—139/826 (16.8%)787/826 (95.3%)
Most frequent serious events
Showing 10 of 124
Most frequent serious events
EventPlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total BG00012
Multiple Sclerosis RelapseNervous system disorders60/40839/41032/41671/826
GastroenteritisInfections and infestations0/4084/4101/4165/826
GastritisGastrointestinal disorders0/4080/4103/4163/826
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4080/4101/4161/826
DepressionPsychiatric disorders2/4081/4100/4161/826
Tendon RuptureInjury, poisoning and procedural complications2/4080/4100/4160/826
PneumoniaInfections and infestations1/4082/4100/4162/826
GoitreEndocrine disorders0/4081/4102/4162/826
HeadacheNervous system disorders0/4080/4102/4162/826
Ovarian CystReproductive system and breast disorders1/4081/4102/4163/826
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total BG00012
MULTIPLE SCLEROSIS RELAPSENervous system disorders181/408109/410107/416216/826
FLUSHINGVascular disorders20/408153/410132/416285/826
NASOPHARYNGITISInfections and infestations101/408108/410109/416217/826
HEADACHENervous system disorders80/40881/41078/416159/826
DIARRHEAGastrointestinal disorders55/40862/41078/416140/826
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations53/40863/41051/416114/826
FATIGUEGeneral disorders54/40857/41063/416120/826
BACK PAINMusculoskeletal and connective tissue disorders57/40859/41046/416105/826
URINARY TRACT INFECTIONInfections and infestations53/40855/41054/416109/826
NAUSEAGastrointestinal disorders38/40853/41054/416107/826

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Mean38.5 ± 9.1438.1 ± 9.1138.8 ± 8.8538.5 ± 9.03
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Female306296306908
Male102114110326
Mean Expanded Disability Status Scale (EDSS) score
Mean Expanded Disability Status Scale (EDSS) score(units on a scale)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Mean2.48 ± 1.2412.40 ± 1.2902.36 ± 1.1882.42 ± 1.240
Mean number of relapses within the previous 3 years
Mean number of relapses within the previous 3 years(Number of relapses)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Mean2.5 ± 1.562.5 ± 1.442.4 ± 1.272.5 ± 1.43
Mean number of relapses within the past 12 months
Mean number of relapses within the past 12 months(Number of relapses)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Mean1.3 ± 0.671.3 ± 0.671.3 ± 0.601.3 ± 0.65
Time since first multiple sclerosis (MS) diagnosis
Time since first multiple sclerosis (MS) diagnosis(Years)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Mean5.8 ± 5.785.6 ± 5.395.1 ± 5.295.5 ± 5.49
Mean number of gadolinium (Gd) enhancing lesions
Mean number of gadolinium (Gd) enhancing lesions(Number of Gd enhancing lesions)PlaceboBG00012 240 mg Twice Daily (BID)BG00012 240 mg 3 Times Daily (TID)Total
Mean1.6 ± 3.451.2 ± 3.301.2 ± 4.101.4 ± 3.64
08

Study locations

160 sites
  • Research Site
    Gilbert, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    New Haven, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Vero Beach, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Evanston, Illinois, United States
  • Research Site
    Palos Heights, Illinois, United States
  • Research Site
    Fort Wayne, Indiana, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Des Moines, Iowa, United States
  • Research Site
    Wichita, Kansas, United States
  • Research Site
    Lexington, Kentucky, United States
  • Research Site
    Brighton, Massachusetts, United States
  • Research Site
    Hopedale, Massachusetts, United States
  • Research Site
    Lexington, Massachusetts, United States
  • Research Site
    Springfield, Massachusetts, United States
  • Research Site
    Worcester, Massachusetts, United States
  • Research Site
    Farmington Hills, Michigan, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Henderson, Nevada, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Lebanon, New Hampshire, United States
  • Research Site
    Albany, New York, United States
  • Research Site
    Staten Island, New York, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Dayton, Ohio, United States
  • Research Site
    Erie, Pennsylvania, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    East Providence, Rhode Island, United States
  • Research Site
    Providence, Rhode Island, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Newport News, Virginia, United States
  • Research Site
    Wien, Virginia, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Camperdown, New South Wales, Australia
  • Research Site
    Chatswood, New South Wales, Australia
  • Research Site
    Fitzroy, Australia
  • Research Site
    Geelong, Australia
  • Research Site
    Heidelberg, Australia
  • Research Site
    Kogarah, Australia
  • Research Site
    Liverpool, Australia
  • Research Site
    Melbourne, Australia
  • Research Site
    Newcastle, Australia
  • Research Site
    Wien, Vienna, Austria
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Linz, Austria
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Brugge, Belgium
  • Research Site
    Charleroi, Belgium
  • Research Site
    Diepenbeek, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Lommel, Belgium
  • Research Site
    Sijsele-Damme, Belgium
  • Research Site
    Woluwe, Belgium
  • Research Site
    Banja Luka, Republic of Srpksa, Bosnia and Herzegovina
  • Research Site
    Burnaby, British Columbia, Canada
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Levis, Quebec, Canada
  • Research Site
    Quebec City, Quebec, Canada
  • Research Site
    Regina, Saskatchewan, Canada
  • Research Site
    Montreal, Canada
  • Research Site
    Zagreb, Croatia
  • Research Site
    Brno, Czech Republic
  • Research Site
    Jihlava, Czech Republic
  • Research Site
    Opava, Czech Republic
  • Research Site
    Ostrava, Czech Republic
  • Research Site
    Plzen, Czech Republic
  • Research Site
    Praha, Czech Republic
  • Research Site
    Teplice, Czech Republic
  • Research Site
    Clermont Ferrand, France
  • Research Site
    Nice, France
  • Research Site
    Paris, France
  • Research Site
    Rennes, France
  • Research Site
    Bad Neustadt-Saale, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Bochum, Germany
  • Research Site
    Dusseldorf, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Gieben, Germany
  • Research Site
    Halle, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Minden, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Munster, Germany
  • Research Site
    Osnabruck, Germany
  • Research Site
    Westerstede, Germany
  • Research Site
    Athens, Greece
  • Research Site
    Ioannina, Greece
  • Research Site
    Thessaloniki, Greece
  • Research Site
    Guatemala City, Guatemala
  • Research Site
    Chenna, India

Showing the first 100 of 160 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Chen C, Parks B, Miller C. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020 May 12;13:1756286420915005. doi: 10.1177/1756286420915005. eCollection 2020. Erratum In: Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420968357. doi: 10.1177/1756286420968357. PubMed 32426039 ↗
  • Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27. PubMed 30918100 ↗
  • Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. Neurol Ther. 2017 Dec;6(2):175-187. doi: 10.1007/s40120-017-0077-5. Epub 2017 Aug 2. PubMed 28770420 ↗
  • Fernandez O, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25. PubMed 28751099 ↗
  • Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017 Feb;33(2):175-183. doi: 10.1080/03007995.2016.1248380. Epub 2016 Nov 10. PubMed 27733070 ↗
  • Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther. 2016 Jun;5(1):45-57. doi: 10.1007/s40120-016-0042-8. Epub 2016 Mar 1. PubMed 26932146 ↗
  • Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clin Ther. 2015 Nov 1;37(11):2543-51. doi: 10.1016/j.clinthera.2015.09.011. Epub 2015 Oct 31. PubMed 26526385 ↗
  • Nakamura K, Brown RA, Narayanan S, Collins DL, Arnold DL; Alzheimer's Disease Neuroimaging Initiative. Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. Neuroimage. 2015 Sep;118:126-32. doi: 10.1016/j.neuroimage.2015.05.077. Epub 2015 Jun 3. PubMed 26049148 ↗
  • Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther. 2014 Dec 1;36(12):1958-1971. doi: 10.1016/j.clinthera.2014.08.013. Epub 2014 Oct 12. Erratum In: Clin Ther. 2018 May;40(5):812. doi: 10.1016/j.clinthera.2018.02.005. PubMed 25315404 ↗
  • Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22. PubMed 24131282 ↗
  • Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287. Erratum In: N Engl J Med. 2012 Dec 13;367(24):2362. PubMed 22992073 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 4 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2007
First posted
Jan 11, 2007
Start
Jan 2007
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results delay requested
Oct 31, 2012
Results first posted
Jun 2, 2014
Last update
Jan 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00420212
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jan 11, 2007
Start date
Jan 2007
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Jun 2, 2014
Last update
Jan 26, 2015

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion